Why these 4 ASX shares have started the week in the red

In afternoon trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has disappointingly slipped under the 6,000 points level for the first time since mid-December. At the time of writing the benchmark index is down 0.15% to 5,997 points.

Four shares which have weighed on the market today are listed below. Here’s why they have started the week in the red:

The Australian Pharmaceutical Industries Ltd (ASX: API) share price has fallen almost 4% to $1.47 following the release of a trading update. Due largely to suppressed retail conditions experienced by its Priceline brand, first-half net profit after tax is expected to come in 9% lower than the prior corresponding period at $26.5 million. Management does, however, expect full-year profit to be slightly above FY 2017’s result.

The Domain Holdings Australia Ltd (ASX: DHG) share price has plunged 11% to $2.95 following the shock resignation of its CEO Antony Catalano. According to the release, Mr Catalano has tendered his resignation just two months after its spin-off due to family commitments. Domain also took this opportunity to advise that its total revenue has grown 13% compared to the prior corresponding period.

The Fairfax Media Limited (ASX: FXJ) share price is down almost 7% to 67.2 cents following the aforementioned departure of Antony Catalano from its spun-off Domain business. Fairfax Media’s shares are down today due to the company’s holding in the property listings company. At the time of the spin-off in November, Fairfax Media was left with a 60% stake in Domain Holdings Australia.

The Mayne Pharma Group Ltd (ASX: MYX) share price has tumbled almost 5.5% to 70.5 cents. The pharmaceutical company’s shares have rallied strongly over the last couple of weeks on the back of no news. In light of this, I suspect that today’s decline could be a case of profit taking from day traders.

Does you portfolio need a lift after these declines? Then don't miss out on these top blue-chip shares.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Pharmaceutical Industries Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.